Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus ONGLYZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus ONGLYZA.
JANUVIA vs ONGLYZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
100 mg orally once daily
2.5 mg or 5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor